For a better understanding of the clinical relevance of the ELF3-AS1 expression in glioma, we divided the 182 glioma patients into a group with a high expression (n = 90) and a group with a low expression (n = 92), taking into account the median ELF3-AS1 expression level (5.232) in all glioma samples. The gene discussed is ELF3; the disease is central nervous system cancer.